Advances in Bioresearch
Adv. Biores., Vol 15 (2) March 2024: 07-12

Print ISSN 0976-4585; Online ISSN 2277-1573
Journal's URL:http://www.soeagra.com/abr.html
CODEN: ABRDC3
DOI: 10.15515/abr.0976-4585.15.2.712

Advances in Bioresearch

REVIEW ARTICLE

Role of Inflammation in Atherosclerosis: A Critical Review of Mechanisms and Therapeutic Implications

1 Prashant S. Pawar, 1 Abhijeet B.Shelke, 1 Vijaysinh Rajaram Patil, 2V. C. Patil
1 Department of Cardiology ,Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth, Karad, Maharashtra
2 Department of General Medicine Krishna Institute of Medical Sciences, Krishna Vishwa Vidyapeeth Deemed To Be University, Karad

ABSTRACT
Globally, atherosclerosis, a complex chronic inflammatory disease, continues to be a major contributor to cardiovascular morbidity and mortality. In order to identify disease causes and investigate therapeutic approaches, it is essential to comprehend the complex interactions between inflammation and atherogenesis. This thorough analysis explains the many causes and implications for new treatment approaches while critically examining the complex roles that inflammation plays in atherosclerosis. Atherosclerosis, which is triggered by endothelial dysfunction and sustained by complex inflammatory pathways, is characterised by the coordinated mobilisation of immune cells, the discharge of pro-inflammatory mediators, and the enhancement of oxidative stress in artery walls. Leukocyte recruitment, foam cell production, and plaque destabilisation are all intricately regulated by inflammatory signalling cascades that involve chemokines, adhesion molecules, and cytokines (e.g., TNF-α, IL-6). Furthermore, by producing reactive oxygen species (ROS), oxidative stress intensifies inflammation and increases the susceptibility of plaque to problems. The critical roles that immune cell subsets, such as mast cells, T lymphocytes, and monocytes/macrophages, play in forming the inflammatory milieu inside atherosclerotic plaques are also examined in this study. The reciprocal link between oxidative stress and inflammation is shown by the way these processes interact, further emphasising the course of illness. Prospective paths for managing atherosclerosis include targeted therapeutic approaches that try to modify certain inflammatory mediators, immune cell responses, or oxidative stress pathways. To reduce cardiovascular risk and mitigate inflammation, lifestyle adjustments and precision medicine techniques are an effective combination to supplement standard medication. In summary, understanding the intricate role that inflammation plays in atherosclerosis clarifies possible treatment targets and raises the prospect of novel approaches to the fight against cardiovascular disorders.
Keywords*: Atherosclerosis, Inflammation, Immune Cells, Oxidative Stress, Therapeutics.*

Received 11.02.2024 Revised 01.03.2024 Accepted 21.03.2024

How to cite this article:
Prashant S. Pawar, Abhijeet B.Shelke, Vijaysinh Rajaram Patil, V. C. Patil. Role of Inflammation in Atherosclerosis: A Critical Review of Mechanisms and Therapeutic Implications. Adv. Biores., Vol 15 (2) March 2024: 07-12.

INTRODUCTION

One of the main causes of cardiovascular illnesses and a major cause of morbidity and death worldwide is atherosclerosis. Extensive research conducted in the last several decades has revealed inflammation as a key component in the complex pathophysiology of atherosclerosis [1].

A Complex Inflammatory Disorder Called Atherosclerosis

Atherosclerosis, which is characterised by the gradual build-up of lipids and fibrous components in artery walls, impairs regular vascular function and can result in serious clinical consequences such as myocardial infarction and stroke [2]. Although it has traditionally been seen of primarily a lipid-driven condition, new research highlights the critical role that inflammatory processes play in the disease's onset and development [3].

Inflammation and Atherogenesis Are Associated

Circulating lipoproteins can infiltrate the subendothelial region due to the first cause of endothelial dysfunction [4]. This is the first in a sequence of inflammatory cascades within the artery wall, aided by malfunctioning endothelium.

Participation of Molecules and Cells in Atherogenic Inflammation

Important players in atherosclerosis, macrophages consume oxidised lipoproteins and develop into foam cells that gather inside artery walls [5]. This build-up encourages the recruitment of T lymphocytes and mast cells, among other immune cells, in conjunction with local inflammatory stimuli [6]. Their coordinated interaction creates an inflammatory milieu in atherosclerotic plaques, which furthers the evolution of the lesion.

Atherosclerosis's Inflammation Mediators

Tumour necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6) are two examples of cytokines that have a significant impact on leukocyte recruitment and endothelial activation, which exacerbates atherosclerosis [7]. Leukocyte trafficking and adherence to endothelial surfaces are tightly regulated by chemokines and adhesion molecules, which sustain inflammatory reactions [8].

Exposing Oxidative Stress as a Provocateur of Inflammation

Reactive oxygen species (ROS), which are produced by oxidative stress and inflammation together, are responsible for the persistence of atherosclerosis [9]. These ROS increase inflammatory signalling cascades and worsen lipid oxidation, which makes plaque more susceptible to rupture [10].

Understanding the underlying inflammatory pathways to find new treatment targets has become increasingly important as the role of inflammation in atherosclerosis becomes more widely acknowledged. Cutting the risk of cardiovascular disease by stopping or reversing the course of atherosclerosis is a potential goal of novel therapeutics that target immune cell responses and inflammatory mediators.

In conclusion, the goal of this study is to examine in detail the complex interactions that exist between inflammation and atherosclerosis. We want to elucidate the critical role that inflammation plays in atherogenesis in order to identify promising treatment pathways that have the potential to transform the management of cardiovascular disease.

Section 1: Atherosclerosis's Inflammatory Pathways

Previously believed to be only a lipid-driven process, atherosclerosis is now recognised as a complicated inflammatory disease that is controlled by a multitude of molecular and cellular mechanisms [1]. The various phases of atherosclerosis are closely linked to inflammation, both as a cause and a result, which has a substantial impact on the onset, course, and final consequences of the disease.

Dysfunction of Endothelium: An Advancement Towards Inflammation

In order to maintain vascular homeostasis, the endothelium—a dynamic contact between circulating blood and artery walls—is essential. A series of crucial processes that are essential to atherogenesis are set in motion by endothelial dysfunction, which is frequently triggered by risk factors including smoking, hypertension, and hyperlipidemia [2].

Increased permeability in dysfunctional endothelial cells makes it easier for lipoproteins to enter the subendothelial space, especially low-density lipoprotein (LDL) [3]. These altered lipoproteins experience oxidative changes within the intima, which makes them immunogenic and able to trigger inflammatory reactions [4].

Atherogenesis's Inflammatory Mediators

Numerous cytokines, chemokines, and adhesion molecules that coordinate cellular contacts and inflammatory cascades inside the artery wall are essential components of the inflammatory milieu in atherosclerosis [5]. Strong pro-inflammatory cytokine tumour necrosis factor-alpha (TNF-α) stimulates adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) in endothelial cells [6].

In addition to encouraging the hepatic manufacture of acute-phase proteins, another important cytokine, interleukin-6 (IL-6), also aids in endothelial activation and leukocyte recruitment [7]. These mediators increase circulating monocyte recruitment and adherence to active endothelium, which in turn triggers the monocytes' conversion into macrophages inside the vessel wall [8].

Macrophages and the Formation of Foam Cells

Macrophages, which are important participants in atherosclerosis, become lipid-laden foam cells when they swallow modified LDL particles through scavenger receptors [9]. Early atherosclerotic lesions are characterised by an excessive concentration of these foam cells within the intima, which plays a crucial role in the creation and progression of plaque.

The Function of Inflammatory Signalling and Inflammasomes

Intracellular multiprotein complexes called inflammasomes have been linked to atherosclerosis in recent investigations [10]. When macrophages' inflammasomes are activated, pro-inflammatory cytokines including interleukin-1β (IL-1β) are released, which intensifies the inflammatory environment in atherosclerotic lesions.

Furthermore, a number of signalling pathways, including as mitogen-activated protein kinase (MAPK) and nuclear factor-kappa B (NF-κB), function as important regulators of the expression of inflammatory genes in atherosclerosis [2,10]. Numerous inflammatory stimuli can trigger these signalling cascades, which then continue to promote foam cell production, leukocyte recruitment, and endothelial activation.

Future Directions and Therapeutic Implications

Numerous treatment strategies become available as the complex inflammatory processes in atherosclerosis are understood. Attenuating the course of atherosclerosis and lowering the risk of cardiovascular disease may be possible with interventions that target particular inflammatory mediators, limit inflammasome activation, or modify cytokine signalling [1,2].

Section 2: The Role of Immune Cells in Atherosclerosis

The complex interaction between atherosclerosis and immune cells drives a complex and dynamic inflammatory response in arterial walls [1]. Numerous immune cell types actively contribute to the development, advancement, and complications of atherosclerotic plaques, such as mast cells, T lymphocytes, and monocytes/macrophages.

Macrophages and Monocytes: Important Players in the Development of Lesion

After being exposed to local cytokines and chemokines, monocytes that have been recruited from the circulation into the subendothelial region develop into macrophages [2]. These macrophages have a variety of functions, including secreting inflammatory mediators, phagocytosing changed lipoproteins, and adjusting plaque stability [3].

Different macrophage phenotypes, such as the traditionally activated M1 and the alternatively activated M2 phenotypes, are produced by the malleability of these cells within atherosclerotic lesions [4]. M2 macrophages aid in tissue healing and lesion stabilisation, whereas M1 macrophages promote inflammation and plaque development.

T Lymphocytes: Regulating Plaque Inflammatory Reactions

T cells, including CD4+ and CD8+ subsets, penetrate atherosclerotic lesions and influence plaque inflammation and stability in different ways [5]. Differentiating into effector subtypes like Th1, Th2, and regulatory T cells (Tregs), CD4+ T cells each play a unique role in the pathophysiology of atherosclerosis.

Th1 cells exacerbate inflammatory responses within plaques by secreting interferon-gamma (IFN-γ) and activating macrophages [6]. On the other hand, Th2 cells have anti-inflammatory characteristics that may mitigate plaque inflammation. Tregs, which are essential for preserving immunological tolerance, reduce inflammation and may even stabilise plaques [7].

Mast Cells: Inflammatory and Plaque Instability Regulators

Activation of mast cells in atherosclerotic lesions results in the production of several inflammatory mediators, including as histamine, cytokines, and proteases [8]. These mediators contribute to a pro-inflammatory milieu within plaques by influencing endothelial activation, leukocyte recruitment, and plaque destabilisation.

Immune Cell Interactions: Affecting the Plaque Phenotype

Lesion stability and development are determined by the complex interactions between immune cell subsets inside the plaque microenvironment [9]. Interactions among macrophages, T cells, and mast cells regulate inflammation, impacting the phenotype of plaque and its susceptibility to rupture, which is a crucial factor in the development of acute cardiovascular events.

Targeting Immune-Mediated Inflammation Has Therapeutic Implications

Gaining insight into the critical functions of immune cells in atherosclerosis provides opportunities for focused treatment approaches. Modulating immune cell recruitment, phenotypic switching, or activation is a promising strategy for stabilising susceptible lesions and changing the composition of plaque [10].

Section 3: Oxidative Stress's Contribution to Atherosclerosis

Atherosclerosis's defining feature, oxidative stress, emerges as a crucial mediator that amplifies inflammation and considerably accelerates the course of the disease [1]. A key factor in the development of atherogenesis is the delicate balance that exists between the vascular milieu's generation of reactive oxygen species (ROS) and antioxidant defence systems.

Endocrine dysfunction and the production of ROS

Endothelial dysfunction is primarily caused by reactive oxygen species, which are produced by inflammatory cells, mitochondria, and NADPH oxidases, among other biological sources [2]. Elevated generation of reactive oxygen species (ROS) outpaces the body's natural antioxidant defences, leading to lipoprotein oxidative alterations and reducing the bioavailability of endothelial nitric oxide.

Oxidative stress results in reduced nitric oxide (NO) availability, which upsets endothelial homeostasis and promotes leukocyte adhesion, platelet activation, and vasoconstriction [3]. These occurrences signal the start of atherosclerosis and establish the stage for the formation of plaque.

Lipid Oxidation: Connecting Inflammation and Oxidative Stress

One important step in the aetiology of atherosclerosis is the oxidative alteration of low-density lipoprotein particles within the artery wall [4]. When oxidised low-density lipoprotein (oxLDL), which is produced by reactive oxygen species (ROS)-mediated lipid peroxidation, interacts with macrophage scavenger receptors, it triggers strong inflammatory reactions that increase plaque inflammation and foam cell production.

Amplification of Inflammatory Signalling by ROS

In atherosclerotic lesions, reactive oxygen species function as secondary messengers, enhancing inflammatory signalling cascades [5]. Redox-sensitive transcription factors, such as nuclear factor-kappa B (NF-κB), are activated by ROS, which sustains the production of pro-inflammatory genes, such as adhesion molecules and cytokines.

Oxidative Stress and Vulnerability of Plaques

One important factor that determines cardiovascular events is the interaction between oxidative stress and plaque vulnerability [6]. The extracellular matrix is broken down by ROS, and this, together with changes in collagen turnover, leads to the destabilisation of plaque and raises the possibility of rupture and thrombotic events.

Mechanisms of Antioxidant Defence: Counteracting Oxidative Stress

Endogenous antioxidant systems are essential defence mechanisms against oxidative stress. They consist of both enzymatic (such as catalase and superoxide dismutase) and non-enzymatic (such as glutathione, vitamin C, and E) components [7]. Their potential therapeutic importance in atherosclerosis is highlighted by their actions in scavenging reactive oxygen species (ROS) and counteracting oxidative damage.

Benefits of Treatment: Addressing Oxidative Stress

Increasing natural antioxidant defences or specifically targeting ROS-producing enzymes have been the main strategies used to combat oxidative stress in atherosclerosis [8]. Potential methods to lessen oxidative stress and its negative impact on the development of atherosclerotic plaque include antioxidant-based therapy and inhibitors of ROS-generating pathways.

In summary, oxidative stress is connected to inflammation and plaque instability and is a key factor in atherosclerosis. Gaining knowledge of the complex relationship between the production of reactive oxygen species (ROS) and antioxidant defences can lead to therapeutic approaches that slow the advancement of atherosclerosis and lower the risk of cardiovascular disease.

Section 4: The Relationship Between Inflammation and Oxidative Stress in Atherosclerosis

One important axis in the pathophysiology of atherosclerosis is the complex interaction between oxidative stress and inflammation, which works in concert to accelerate the disease's development [1].

ROS as Inflammatory Signalling Mediators

In atherosclerotic lesions, reactive oxygen species (ROS) are important mediators that intensify inflammatory signalling cascades [2]. Plaque inflammation persists because ROS-mediated activation of redox-sensitive transcription factors, particularly nuclear factor-kappa B (NF-κB), increases the expression of genes that promote inflammation.

Lipid Oxidation and Inflammatory Reactions Induced by ROS

ROS-mediated oxidative alteration of LDL particles sets off a series of events that promote inflammatory responses in the artery wall [3]. Local inflammation is exacerbated by oxidised low-density lipoprotein (oxLDL), which is a strong inducer of endothelial activation. This process encourages leukocyte adherence and subsequent infiltration into the vessel wall.

Proliferating Cells as ROS Sources

Within atherosclerotic lesions, immune cells such as neutrophils and macrophages are important producers of reactive oxygen species (ROS) [4]. When these cells are activated, NADPH oxidase and myeloperoxidase generate reactive oxygen species (ROS), which intensify oxidative stress and prolong inflammatory reactions.

Oxidative Stress-Sustained Endothelial Failure

One of the key processes in atherogenesis, endothelial function, is severely compromised by oxidative stress [5]. A pro-inflammatory and pro-thrombotic milieu is fostered by reduced nitric oxide (NO) bioavailability, which is caused by ROS-mediated NO degradation. This reduces vasodilation and increases endothelial activation.

Inflammation and Oxidative Stress Mutual Potentiation

The link between oxidative stress and inflammation in atherosclerotic lesions is reciprocal, with each feeding and maintaining the other [6]. The formation of ROS is boosted by inflammatory mediators such chemokines and cytokines, and ROS in turn intensifies inflammatory signalling cascades, resulting in a vicious cycle of inflammation and damage that reinforces itself.

Treatment Methods for the Oxidative-Inflammatory Axis

Promising treatment options for atherosclerosis involve addressing the interaction between inflammation and oxidative stress [7]. Strategies that concentrate on reducing oxidative stress by employing antioxidants or controlling inflammatory reactions by using anti-inflammatory drugs seek to break the vicious cycle and maybe slow the advancement of atherosclerosis.

In conclusion, oxidative stress and inflammation are closely related, and this interaction is crucial to the pathophysiology of atherosclerosis. Comprehending and focusing on this complex axis might provide new approaches to the treatment of atherosclerotic cardiovascular illnesses by treating inflammation and oxidative stress.

Section 5: Therapeutic Implications: Atherosclerosis Treatment Through Inflammatory Pathways

The complex role that inflammatory pathways play in atherosclerosis has opened the door to the investigation of focused treatment approaches meant to slow down the evolution of the disease and reduce the risk of cardiovascular events [1].

Strategies to Reduce Inflammation

One effective way to manage atherosclerosis is to inhibit certain inflammatory mediators [2]. It has been demonstrated that utilising soluble receptor antagonists or monoclonal antibodies to target important cytokines like TNF-α or IL-6 can reduce cardiovascular events and modulate inflammation.

Adjustment of Immune Cell Reactions

Modulating immune cell morphologies or functions is a promising strategy to modify the stability and composition of plaque [3]. Potential therapeutic advantages in the management of atherosclerosis can be obtained by promoting the transition of pro-inflammatory M1 macrophages towards a more anti-inflammatory M2 phenotype or by increasing regulatory T cell activity.

Inhibition of Inflammatory Signalling and Inflammasomes

It is becoming more and more appealing to target inflammasomes, which are essential for exacerbating inflammatory reactions [4]. Stabilising atherosclerotic lesions and reducing plaque inflammation may be achieved by blocking downstream signalling pathways or inflammasome activation.

Changes in Lifestyle and Pharmacotherapy

Lifestyle modifications continue to be essential in the management of atherosclerosis even in the absence of particular targeted methods [5]. In order to reduce inflammation and cardiovascular risk, strategies that emphasise healthy diets, regular exercise, quitting smoking, and effective treatment of risk factors—such as hypertension and hyperlipidemia—complement medication.

Methods in Personalised Medicine

Precision medicine's latest developments attempt to customise treatment plans according to each patient's unique attributes, such as biomarker profiles and genetic susceptibility [6]. Tailored strategies for inflammatory pathway targeting may improve treatment outcomes and reduce side effects.

Obstacles and Prospects for the Future

The integration of anti-inflammatory therapies into clinical practice continues to present difficulties, despite encouraging developments [7]. There are constant difficulties in the sector in identifying the best treatment targets, choosing the best time and length for interventions, and managing any possible adverse effects.

The care of atherosclerosis will probably change in the future due to the integration of innovative therapeutic agents, precision medicine techniques, and lifestyle modifications in multidisciplinary methods. A thorough comprehension of inflammatory pathways provides optimism for novel strategies meant to lessen the burden of cardiovascular illnesses.

REFERENCES

1. Libby, P. (2002). Inflammation in atherosclerosis. Nature, 420(6917), 868-874. https://doi.org /10.1038/nature01323
2. Hansson, G. K., & Hermansson, A. (2011). The immune system in atherosclerosis. Nature Immunology, 12(3), 204-212. https://doi.org/10.1038/ni.2001
3. Weber, C., & Noels, H. (2011). Atherosclerosis: Current pathogenesis and therapeutic options. Nature Medicine, 17(11), 1410-1422. https://doi.org/10.1038/nm.2538
4. Gimbrone, M. A. Jr, & García-Cardeña, G. (2016). Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circulation Research, 118(4), 620-636. https://doi.org/10.1161/CIRCRESAHA.115.306301
5. Stocker, R., & Keaney, J. F. Jr. (2004). Role of oxidative modifications in atherosclerosis. Physiological Reviews, 84(4), 1381-1478. https://doi.org/10.1152/physrev.00047.2003
6. Förstermann, U., Xia, N., & Li, H. (2017). Roles of vascular oxidative stress and nitric oxide in the pathogenesis of atherosclerosis. Circulation Research, 120(4), 713-735. https://doi.org/10.1161/ CIRCRESAHA. 116.309326

7. Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., ... & Latz, E. (2010). NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature, 464(7293), 1357-1361. https://doi.org/10.1038/nature08938
8. Libby, P. (2013). Mechanisms of acute coronary syndromes and their implications for therapy. New England Journal of Medicine, 368(21), 2004-2013. https://doi.org/10.1056/NEJMra1216063
9. Moore, K. J., & Tabas, I. (2011). Macrophages in the pathogenesis of atherosclerosis. Cell, 145(3), 341-355. https://doi.org/10.1016/j.cell.2011.04.005
10. Harrison, D. G., Guzik, T. J., Lob, H. E., Madhur, M. S., Marvar, P. J., Thabet, S. R.,& Weyand, C. M. (2011). Inflammation, immunity, and hypertension. Hypertension, 57(2), 132-140. https://doi.org/10.1161/HYPERTENSIONAHA.110.163576